20/20 Biolabs, Inc.

EFFECT effective

S-1 filed

10,105,000 shares

20/20 Biolabs, Inc. is registering 10,105,000 shares of common stock for resale by a selling stockholder, including shares from previous issuances, warrant exercises, and convertible instruments. The company develops AI-powered lab tests for cancer and chronic disease detection, with two primary products: OneTest for Cancer (MCED) and OneTest for Longevity. The filing emphasizes the company's emerging growth status, regulatory risks, and reliance on third-party labs. Proceeds from warrant exercises will benefit the company, while the selling stockholder's sales will not.

424B3 filed

20/20 Biolabs, Inc. is conducting a direct listing on Nasdaq under the ticker AIDX, with 15,164,724 shares of common stock registered for resale by selling stockholders. Unlike an IPO, the offering is not underwritten, and the company will not receive proceeds from the resale. The stock will commence trading on February 19, 2026, with Nasdaq managing the price-setting process through a pre-opening mechanism involving Maxim Group LLC as the financial advisor. The direct listing method introduces risks related to volatility and trading volume compared to traditional underwritten offerings.

EFFECT effective

20/20 Biolabs, Inc. filed an S-1 registration statement effective February 17, 2026, registering common stock for listing on The Nasdaq Stock Market LLC. The filing incorporates by reference information from the company's Registration Statement on Form S-1 (File No. 333-292125), including details about its capital structure and securities. This follows a prior 8-A12B filing for registration of certain securities under Section 12(b) of the Securities Exchange Act.

8-A12B effective

20/20 Biolabs, Inc. filed Form 8-A12B to register its common stock for listing on Nasdaq, referencing information from its prior S-1/A registration statement. The filing confirms the company's transition to a publicly traded entity under Section 12(b) of the Securities Exchange Act, with no new material disclosures beyond incorporating prior S-1/A details.

S-1/A amended

20/20 Biolabs, Inc. filed Amendment No. 2 to its S-1 registration statement for a direct listing on Nasdaq, focusing on adding exhibits and omitting the preliminary prospectus. The company remains an emerging growth company, with no underwriter involved in the resale of 15,164,724 shares by selling stockholders. The filing emphasizes the novel direct listing process, lack of public market history, and potential volatility in trading volume and price.

S-1/A amended

15,164,724 shares

20/20 Biolabs, Inc. is registering 15,164,724 shares of common stock for resale via a direct listing on Nasdaq, bypassing traditional underwriting. The company focuses on AI-powered blood tests for cancer detection (OneTest for Cancer) and longevity biomarkers (OneTest for Longevity). Revenue comes primarily from OneTest for Cancer, with additional income from BioCheck and CLIAx services. The filing highlights risks related to its novel direct listing structure, reliance on a single product, and regulatory uncertainties.

S-1 filed

15,130,055 shares · Gross proceeds $0.00

20/20 Biolabs, Inc. is registering 15,130,055 shares of common stock for resale via a direct listing on Nasdaq, bypassing a traditional IPO. The company focuses on AI-powered blood tests for cancer and chronic disease detection, with its OneTest for Cancer product accounting for ~87% of revenue. The filing outlines a novel listing process without underwriters, relying on Nasdaq's price-setting mechanism and a financial advisor, Maxim Group LLC. The company also highlights its CLIA-accredited lab and expansion into longevity testing.

DRS/A amended

20/20 Biolabs, Inc. is registering shares for resale by selling stockholders as part of a direct listing on Nasdaq, bypassing traditional underwriting. The company develops AI-powered blood tests for cancer and chronic disease detection, with revenue from its OneTest for Cancer, BioCheck, and CLIAx services. The filing outlines the direct listing process, including Nasdaq's price-setting mechanism and risks associated with the novel listing method. The company remains an emerging growth entity with reduced reporting requirements.

DRS filed

20/20 Biolabs, Inc. is registering shares of common stock for resale by selling stockholders in connection with a direct listing on Nasdaq, not an IPO. The company develops AI-powered blood tests for cancer and chronic disease detection, operating a CLIA-accredited lab. The filing emphasizes a novel direct listing approach without underwriters, with shares to be sold via Nasdaq at market prices. The company generates revenue from its OneTest for Cancer, BioCheck, and CLIAx services.

DRS/A amended

20/20 Biolabs, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital through the sale of shares at an estimated price range. The company develops AI-powered blood tests for early cancer detection and chronic disease prevention, with two primary product lines: OneTest for Cancer (MCED) and OneTest for Longevity. The offering follows a name change from 20/20 GeneSystems, Inc., and includes plans to launch a new product in 2025. The company operates a CLIA-accredited lab and a shared diagnostic innovation platform (CLIAx).

DRS/A amended

20/20 GeneSystems, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital through the sale of shares at an estimated price range. The company focuses on developing multi-cancer early detection (MCED) blood tests, particularly its OneTest platform, which uses tumor antigen analysis rather than circulating tumor DNA (ctDNA). The filing highlights growing legislative and market support for MCED tests, including the White House's Cancer Moonshot initiative and state-level funding for firefighters. The company plans to list on NYSE American and emphasizes its proprietary machine learning-driven approach to improve diagnostic accuracy.

DRS/A amended

20/20 GeneSystems, Inc. is a diagnostics company developing multi-cancer early detection (MCED) blood tests using tumor antigen analysis powered by machine learning. The company is conducting an initial public offering (IPO) of common stock, targeting early cancer detection where current screening methods are limited. Their proprietary OneTest platform utilizes proteomic approaches with FDA-cleared platforms, aiming to offer a cost-effective alternative to DNA-based testing. The offering includes underwriting terms and is contingent on NYSE American listing.

DRS/A amended

20/20 GeneSystems, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital through the sale of shares at an estimated price range. The company specializes in developing multi-cancer early detection (MCED) blood tests, with its lead product, OneTest, utilizing tumor antigen measurements rather than circulating tumor DNA (ctDNA). The IPO positions OneTest as a 'top of funnel' screening tool to identify high-risk individuals for further diagnostic evaluation. The company plans to list on NYSE American and is classified as an emerging growth company, benefiting from reduced reporting requirements. The filing emphasizes the potential of its machine learning-driven proteomic approach to improve diagnostic accuracy at lower costs compared to DNA-based tests.

DRS/A amended

20/20 GeneSystems, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital through the sale of shares. The company focuses on developing multi-cancer early detection (MCED) blood tests, with its lead product, OneTest, utilizing tumor antigen measurement rather than circulating tumor DNA (ctDNA). The offering includes underwriting discounts, a 30-day option for over-allotments, and plans to list on NYSE American. The company emphasizes its patented machine learning approach to improve diagnostic accuracy and reduce costs compared to existing methods.

DRS filed

20/20 GeneSystems, Inc. is conducting an initial public offering (IPO) to register shares of its common stock. The company develops diagnostic tests for early disease detection, with a focus on multi-cancer early detection (MCED) blood tests like OneTest, which uses tumor antigen measurement rather than circulating tumor DNA. The filing highlights its CLIAx program, enabling third-party diagnostics startups to launch tests in its licensed lab, and notes its status as an emerging growth company. The IPO aims to fund expansion, with proceeds intended for research, product development, and operational costs.